The SEeMORE strategy: single-tube electrophoresis analysis-based genotyping to detect monogenic diseases rapidly and effectively from conception until birth.

Background: The development of technologies that detect monogenic diseases in embryonic and fetal samples are opening novel diagnostic possibilities for preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND) thereby changing laboratory practice. Molecular diagnos- tic laboratories use different workflows for PND depend- ing on the disease, type of biological sample, the presence of one or more known mutations, and the availability of the proband. Paternity verification and contamination analysis are also performed. The aim of this study was to test the efficacy of a single workflow designed to optimize the molecular diagnosis of monogenic disease in families at-risk of transmitting a genetic alteration. Methods: We used this strategy, which we designated “SEeMORE strategy” (Single-tube Electrophoresis analysis- based genotyping to detect MOnogenic diseases Rapidly and Effectively from conception to birth). It consists of a mul- tiplex PCR that simultaneously carries out linkage analysis, direct analysis, maternal contamination and parenthood testing. We analyzed samples from previously diagnosed families for PND (cystic fibrosis or Duchenne muscular dys- trophy) without, however, knowing the results. Results: The results obtained with the SEeMORE strategy concurred with those obtained with traditional PND. In addition, this strategy has several advantages: (i) use of one or a few cells; (ii) reduction of the procedure to 1 day; and (iii) a reduction of at least 2–3-fold of the analytic cost. Conclusions: The SEeMORE strategy is effective for the molecular diagnosis of monogenic diseases, irrespec- tive of the amount of starting material and of the disease mutation, and can be used for PND and PGD.